



# CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all plans administered by CIGNA Companies including plans administered by Great-West Healthcare, which is now a part of CIGNA.

Effective Date ..... 12/15/2008  
Next Review Date.....9/15/2009  
Coverage Policy Number .....0180

Subject **Aural Rehabilitation**

## Table of Contents

Coverage Policy .....	1
General Background .....	1
Coding/Billing Information .....	4
References .....	5
Policy History.....	7

## Hyperlink to Related Coverage Policies

Cochlear and Auditory Brainstem Implants  
Hearing Aids  
Meniett™ Device  
Neonatal Auditory Screening  
Speech/Language Therapy

### INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans as well as benefit plans formerly administered by Great-West Healthcare. Please note, the terms of a participant's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a participant's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a participant's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable group benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2008 CIGNA

## Coverage Policy

Aural rehabilitation is considered a form of speech therapy. Coverage for outpatient speech therapy is subject to the terms, conditions and limitations of the Short-Term Rehabilitative Therapy benefit as described in the applicable benefit plan's schedule of copayments. Many benefit plans include a maximum allowable speech therapy benefit for duration of treatment or number of visits. When the maximum allowable benefit is exhausted, coverage will no longer be provided even if the medical necessity criteria described below are met.

Some benefit plans specifically exclude maintenance or preventive treatment, consisting of routine, long-term or non-medically necessary care provided to prevent recurrences or to maintain the individual's current status.

CIGNA covers aural rehabilitation as medically necessary for the management of hearing impairment caused by trauma, tumor or disease or following implantation of a cochlear or auditory brainstem device.

CIGNA HealthCare does not cover aural rehabilitation for presbycusis because it is considered experimental, investigational or unproven.

## General Background

Hearing loss, one of the most common sensory disorders, is the consequence of sensorineural and/or conductive malfunctions of the ear. The impairment may be congenital or caused postnatally by trauma or disease. Hearing loss may be pre-lingual (i.e., occurring prior to speech and language acquisition) or post-lingual (i.e., occurring after the acquisition of speech and language).

In conductive hearing loss, an obstruction to air conduction prevents the proper transmission of sound waves through the external auditory canal and/or the middle ear. The auricle (pinna), external acoustic canal, tympanic membrane, or bones of the middle ear may be dysfunctional.

Conductive hearing loss can be congenital or caused by trauma, severe otitis media, otosclerosis, neoplasms, or atresia of the ear canal. Conductive hearing loss is marked by an almost equal loss of all frequencies. Some conductive hearing loss can be treated surgically with tympanoplasty or stapedectomy. Many individuals can also benefit from hearing aids and assistive listening devices.

Sensorineural hearing loss, which is more common than conductive hearing loss, occurs when the sensory receptors of the inner ear are dysfunctional.

Sensorineural deafness is a lack of sound perception caused by a defect in the cochlea and/or the auditory division of the vestibulocochlear nerve. This type of hearing loss is typically irreversible. It tends to be unevenly distributed, with greater loss at higher frequencies. Sensorineural deafness may be congenital or result from intense noise, trauma, viral infections, ototoxic drugs (e.g., Cisplatin, salicylates, loop diuretics), fractures of the temporal bone, meningitis, Ménière's disease, cochlear otosclerosis, aging (i.e., presbycusis), or congenital malformation of the inner ear. Genetic predispositions, either alone or in combination with environmental factors, may be responsible as well.

Many patients with sensorineural hearing loss can be habilitated or rehabilitated with the use of hearing aids. Patients with profound bilateral sensorineural hearing loss (e.g., at least 90 dB) who derive no benefit from conventional hearing aids may be appropriate candidates for cochlear device implantation. The implant bypasses the damaged structures of the cochlea and stimulates the function of the auditory nerve. Cochlear implants cannot be used by individuals with auditory nerve damage. For these individuals, electrode arrays have been designed that can be placed on the cochlear nucleus (American Speech-Language-Hearing Association [ASHA], 2004). Auditory brainstem implants are similar to the multichannel cochlear implants. Brainstem implants are used in patients with neurofibromatosis type 2 who have lost integrity of auditory nerves following vestibular schwannoma removal.

Individuals with mixed hearing loss have both conductive and sensory dysfunction. Mixed hearing loss is due to disorders that can affect the middle and inner ear simultaneously, such as otosclerosis involving the ossicles and the cochlea; head trauma; middle ear tumors; and some inner ear malformations. Trauma resulting in temporal bone fractures may be associated with conductive, sensorineural and mixed hearing loss.

Presbycusis is the general term applied to age-related hearing loss and is used to describe the sum of all the processes that affect hearing over time. Presbycusis affects both of the critical dimensions of hearing by reducing threshold sensitivity as well as the ability to understand speech. Individuals with presbycusis often do not express difficulty hearing, but are more likely to complain of problems understanding speech. Hearing aids are the primary resource for improving communication and reducing hearing handicaps in those with sensorineural presbycusis (Gates and Rees, 2006). Although communication strategies are employed in the management of presbycusis, a comprehensive, structured aural rehabilitation (AR) program is typically not used as a treatment modality for adult-onset hearing loss that is associated with the aging process.

### **Aural Rehabilitation (AR)**

Aural rehabilitation is frequently used as an integral component in the overall management of individuals with hearing loss. According to the American Speech-Language-Hearing Association, AR refers to services and procedures for facilitating adequate receptive and expressive communication in individuals with hearing impairments. Aural rehabilitation is often an interdisciplinary endeavor involving physicians, audiologists and speech-language pathologists. For school-age children, therapy may also be coordinated with the school system. In general, services may be initiated as soon as a patient has been identified as having a hearing impairment, following the fitting of a hearing device or after implantation of a cochlear device. Services involved in the provision of AR include:

- identification and evaluation of sensory capabilities, including extent of impairment and fitting of auditory aids
- interpretation of audiologic findings, plus counseling and referral
- development and provision of an intervention program for communicative disorders to facilitate expressive and receptive communication
- re-evaluation of the patient's status
- evaluation and modification of the intervention program

Although AR programs are accepted and widely used in the management of hearing-impaired individuals, the role of AR in the overall treatment and its impact on health outcomes has not been clearly delineated, other than in those with cochlear device implants.

AR should be structured, systematic, individualized and goal-directed (i.e., both long- and short-term goals). For patients who acquire a hearing loss post-lingually, treatment would be considered rehabilitative and restorative in nature. Although the term "rehabilitation" is commonly used in association with services provided to pre-lingually hearing-impaired patients, treatment would more accurately be described as "habilitative" in nature, as it does not involve restoring a lost function. Both group therapy and computer-based training are often used in aural rehabilitation; however, these methods are not individualized to specific patient needs. The primary focus of many AR components and interventions is training (e.g., speech-reading training, vocational training). This training can occur in group or individual sessions.

Audiologists and speech-language pathologists certified by ASHA are qualified to provide AR components. The audiologist may be responsible for:

- the fitting, dispensing and management of a hearing device
- provision of counseling about hearing loss and processes to enhance communication
- skills training regarding environmental modifications which will facilitate the development of receptive and expressive communication

The speech-language pathologist is typically responsible for evaluating receptive and expressive communication skills and providing services to improve them, as well as for providing training and treatment in communication strategies (e.g., assertive listening tactics), speech-perception training (e.g., speech-reading, auditory training and auditory-visual-speech-perception training), speech and voice production, and comprehension of oral, written and signed language.

AR following cochlear device implantation and auditory brainstem implantation is considered an integral part of the overall management of implant patients. Although programs vary widely, both with regard to treating disciplines and to the duration and scope of treatment, the general consensus is that some type of post-implantation aural therapy maximizes the benefit of the device. Sound recognition and speech intelligibility are evaluated prior to and just after implantation. Hearing capabilities are assessed by an audiologist, both with and without the assistance of a hearing aid. A speech-language pathologist evaluates and categorizes the patient's pre-implantation speech and language skills. Following cochlear device implantation, a program of rehabilitation typically is provided for 20–30 hours in children and 20–25 hours in adults. Post-cochlear implantation rehabilitation programs generally include the following components: sound awareness (e.g., recognition of novel auditory signals); visual/auditory processing, including speech-reading training (e.g., lip-reading, facial expression, gestures and body language); speech recognition; mechanical (e.g., use of the device and telephone); and voice, speech production and language therapy.

Initially, AR records should be provided to substantiate the need for this therapy. Records should include clinical narrative notes from the attending physician or referring provider, with a description of expressive and/or receptive speech impairments and reports of standardized speech and hearing tests, if applicable. An evaluation and treatment plan, including assessment of level of function, measurable long- and short-term goals, progress toward achieving goals, anticipated timeframe for achieving goals, and anticipated frequency and duration of therapy, should also be obtained. For continued treatment, it is necessary to obtain follow-up evaluations, auditory therapy notes, documentation of progress toward goals, and treatment plan revisions.

### **Professional Societies/Organizations**

The ASHA preferred practice patterns for audiology state that AR evaluation for individuals of all ages is prompted by the identification of hearing impairment. AR is indicated for individuals with hearing impairment who experience, or are at risk for, communication problems that impose activity limitations and participation restrictions. AR facilitates the speech-language, cognitive, and social-emotional development and functioning of children with hearing impairment. AR facilitates adjustment to and enhances benefits from the use of hearing aids, cochlear implants, and assistive technologies (ASHA, 2006).

### Summary

A program of aural rehabilitation (AR) usually begins as soon as a hearing impairment is identified. AR is indicated for the treatment of such impairment and is a medically necessary component of the management of cochlear device and auditory brainstem implantation. A systematic, individualized and goal-directed AR program has not been proven to improve health-related quality of life outcomes for individuals with presbycusis and is generally not used as a treatment modality for this indication.

## Coding/Billing Information

**Note:** This list of codes may not be all-inclusive.

### Covered when medically necessary:

CPT®*	Description
92626	Evaluation of auditory rehabilitation status; first hour
92627	Evaluation of auditory rehabilitation status; each additional 15 minutes (List separately in addition to code for primary procedure)
92630	Auditory rehabilitation; pre-lingual hearing loss
92633	Auditory rehabilitation; post-lingual hearing loss

ICD-9-CM Diagnosis Codes	Description
225.1	Acoustic neuroma
387.0 – 387.9	Otosclerosis
388.11	Acoustic trauma (explosive) to the ear
388.12	Noise-induced hearing loss
388.2	Sudden hearing loss, unspecified
388.5	Disorders of the acoustic nerve
389.00 – 389.08	Conductive hearing loss
389.10 – 389.18	Sensorineural hearing loss
389.2	Mixed conductive and sensorineural hearing loss
389.7	Deaf mutism, not elsewhere classifiable
389.8	Other specified forms of hearing loss
389.9	Unspecified hearing loss
951.5	Injury to acoustic nerve/auditory nerve
	Multiple/varied codes

### Experimental/Investigational/Unproven/Not Covered:

ICD-9-CM Diagnosis Codes	Description
388.01	Presbycusis

## References

1. American Speech-Language-Hearing Association (ASHA). Definition of and Competencies for Aural Rehabilitation: Committee on Rehabilitative Audiology. Accessed Aug 4, 2008. Available at URL address: <http://www.asha.org/docs/pdf/RP1984-00207.pdf>
2. American Speech-Language-Hearing Association (ASHA). (2001). Knowledge and Skills Required for the Practice of Audiologic/Aural Rehabilitation: Working Group on Audiologic Rehabilitation. Accessed Aug 4, 2008. Available at URL address: <http://www.asha.org/docs/pdf/KS2001-00216.pdf>
3. American Speech-Language-Hearing Association (ASHA). Adult Aural/Audiologic Rehabilitation. © 1997–2008. Accessed Aug 4, 2008. Available at URL address: [http://www.asha.org/public/hearing/treatment/adult\\_aur\\_rehab.htm](http://www.asha.org/public/hearing/treatment/adult_aur_rehab.htm)
4. American Speech-Language-Hearing Association (ASHA). Aural/ Audiologic Rehabilitation for Children. © 1997–2008. Accessed Aug 4, 2008. Available at URL address: [http://www.asha.org/public/hearing/treatment/child\\_aur\\_rehab.htm](http://www.asha.org/public/hearing/treatment/child_aur_rehab.htm)
5. American Speech-Language-Hearing Association (ASHA). Preferred Practice Patterns for the Profession of Speech-Language Pathology. November, 2004. Accessed Aug 9, 2005. Available at URL address: [http://www.asha.org/NR/rdonlyres/C589BA8F-5931-48AA-8E02-59CF989DC01F/0/18758\\_1.pdf#search='policy%20statements%20aural%20rehabilitation'](http://www.asha.org/NR/rdonlyres/C589BA8F-5931-48AA-8E02-59CF989DC01F/0/18758_1.pdf#search='policy%20statements%20aural%20rehabilitation')
6. American Speech-Language-Hearing Association (ASHA). Preferred Practice Patterns for the Profession of Audiology. December 2006. Accessed Aug 9, 2007. Available at URL address: <http://www.asha.org/docs/pdf/PP2006-00274.pdf>
7. Boothroyd A. Adult aural rehabilitation: what is it and does it work? *Trends Amplif.* 2007 Jun;11(2):63-71.
8. Carney AE, Moeller MP. Treatment Efficacy: Hearing Loss in Children. *JSLHR* 1998 Feb;41:61-84.
9. Chisolm TH, Abrams HB, McArdle R. Short- and long-term outcomes of adult audiological rehabilitation. *Ear Hear.* 2004 Oct;25(5):464-77.
10. Gagne JP, Jennings MB. Audiological Rehabilitation Intervention Services for Adults with Acquired Hearing Impairments. In: Valente M, Hosford-Dunn H, Roeser RJ, editors. *Audiology: Treatment*. New York: Thieme; 2000. p. 547-79.
11. Gates GA, Mills JH. Presbycusis. *Lancet.* 2005 Sep 24-30;366(9491):1111-20.
12. Gates GA, Rees TS. Hear ye? Hear ye! Successful auditory aging. *West J Med.* 1997 Oct;167(4):247-52.
13. HAYES Medical Technology Directory. Cochlear Implantation. Lansdale, PA: HAYES, Inc. ©2007 Winifred S. Hayes, Inc. 2007 Dec.
14. Henderson Sabes J, Sweetow RW. Variables predicting outcomes on listening and communication enhancement (LACE) training. *Int J Audiol.* 2007 Jul;46(7):374-83.
15. Hull RH. What is Aural Rehabilitation? In: Hull RH, editor. *Aural Rehabilitation*. 3rd ed. San Diego: Singular Publishing Group, Inc.: 1997. p. 3-15.

16. Hull RH. Improving Communication for Adults Through Aural Rehabilitation: History, Theory, and Application. In: Hull RH, editor. Aural Rehabilitation, 3rd ed. San Diego: Singular Publishing Group, Inc.; 1997. p. 177-190.
17. Institute for Clinical Systems Improvement (ICSI). Institute for Clinical Systems Integration Technology Assessment Report. Cochlear Implants. 1993 May. Updated 2005 July. Accessed Aug 4, 2004. Available at URL address: <http://www.icsi.org/knowledge/detail.asp?catID=306&itemID=271>
18. National Institutes of Health (NIH). Cochlear Implants in Adults and Children. NIH Consensus Development Statement Online. 1995 May 15-17. Accessed Aug 4, 2004. Available at URL address: [http://consensus.nih.gov/cons/100/100\\_intro.htm](http://consensus.nih.gov/cons/100/100_intro.htm)
19. Neuman AC. Central auditory system plasticity and aural rehabilitation of adults. J Rehabil Res Dev. 2005 Jul-Aug;42(4 Suppl 2):169-86.
20. Sweetow R, Palmer CV. Efficacy of individual auditory training in adults: a systematic review of the evidence. J Am Acad Audiol. 2005 Jul-Aug;16(7):494-504.
21. Sweetow RW, Sabes JH. Technologic advances in aural rehabilitation: applications and innovative methods of service delivery. Trends Amplif. 2007 Jun;11(2):101-11.
22. Tobey EA, Devous MD Sr, Buckley K, Overson G, Harris T, Ringe W, et al. Pharmacological enhancement of aural habilitation in adult cochlear implant users. Ear Hear. 2005 Aug;26(4 Suppl):45S-56S.
23. Tomaski SM, Grundfast KM. A stepwise approach to the diagnosis and treatment of hereditary hearing loss. Pediatr Clin North Am. 1999 Feb;46(1):35-48.
24. Tucci DL, Lambert PR, Ruth RA. Trends in Rehabilitation After Cochlear Implantation. Arch Otolaryngol Head Neck Surg. 1990 May;116(5):571-4.
25. Tyler RS, Tye-Murray N, Gantz BJ. Aural rehabilitation. Otolaryngol Clin North Am. 1991 Apr;24(2):429-45.

---

## Policy History

---

<b>Pre-Merger Organizations</b>	<b>Last Review Date</b>	<b>Policy Number</b>	<b>Title</b>
CIGNA HealthCare	9/15/2008	0180	Aural Rehabilitation

“CIGNA” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided exclusively by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Behavioral Health, Inc., Intracorp, and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. and Great-West Healthcare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company.

Connecticut General Life Insurance Company has acquired the business of Great-West Healthcare from Great-West Life & Annuity Insurance Company (GWLA). Certain products continue to be provided by GWLA (Life, Accident and Disability, and Excess Loss). GWLA is not licensed to do business in New York. In New York, these products are sold by GWLA's subsidiary, First Great-West Life & Annuity Insurance Company, White Plains, N.Y.